Imbruvica

0.0

review 0

Pharmacy & Pharmaceuticals

Contact details

999 east arques avenue, sunnyvale, california, united states, 94085

Company activity

Comprehensive Review

AI-Powered Reviews & Recommendations

This AI-generated summary is based on available data and user feedback when available.

Performance metrics indicate that users have seen positive outcomes while using IMBRUVICA®, particularly regarding improved survival rates compared to traditional chemotherapy options. Feedback emphasizes the importance of patient support services alongside medication adherence. • Survival statistics demonstrate significant advantages over conventional treatments like chlorambucil. • Support initiatives enhance patient experience through education and financial resources availability. • Clinical evidence highlights reduced mortality risk, especially for older adults with CLL/SLL. • Treatment challenges may arise; discussing side effects promptly helps optimize therapy effectiveness.

No review for yet

Be the first to share your experience with this brand!

Reviews With Impact: Making a Difference

Trustima believe every experience deserves to be heard and every voice can make a difference. That's why we've launched our groundbreaking initiative - transforming your honest feedback into concrete environmental action. When you share your experience on our platform, you're not just helping others make informed decisions - you're directly contributing to reforestation efforts.

Start Now

Questions and Answers

Can new patients receive additional resources when starting treatment with IMBRUVICA®?

New patients can inquire about obtaining a free Patient Starter Kit by speaking with their healthcare provider. This kit may provide essential information and support as they begin their treatment journey with IMBRUVICA®.

Why should patients discuss side effects with their healthcare providers while on IMBRUVICA®?

Patients are encouraged to talk about any side effects experienced while taking IMBRUVICA® with their healthcare team. Open communication allows for potential dose adjustments and ensures that treatment plans remain effective based on individual responses.

How does IMBRUVICA® compare to chemotherapy in terms of survival rates for CLL patients?

In a clinical trial involving 269 CLL patients, those taking IMBRUVICA® (ibrutinib) had an 8% death rate compared to a 16% death rate among those on chemotherapy (chlorambucil) after 28 months. This indicates a significant improvement in survival rates with IMBRUVICA®.

Where can individuals find more information about the privacy practices related to personal data collection?

Individuals seeking information about how personal data is collected and processed can visit Pharmacyclics' privacy notice at https://www.pharmacyclics.com/privacy-notice.html#info_pcp, which outlines categories of data collected and purposes for their collection.

What are the eligibility criteria for the IMBRUVICA® copay assistance program?

The IMBRUVICA® copay assistance program is available to patients with commercial insurance coverage who meet specific eligibility criteria. It is not offered to those receiving prescription reimbursement through federal or government-funded programs, including Medicare and Medicaid.